Lermed is dedicated to unleash groundbreaking personalized treatments against neurodegenerative diseases. By embracing a fully integrative approach combining different proprietary platforms, we aim at accelerating drug discovery, derisking clinical trials and unlocking precision medicine in the field of neurodegeneration.

Lermed leverages two fully human platforms. On one hand, our blood-based liquid biopsy technology is tailored to identify relevant biomarkers for drug efficacy and safety as well as patient stratification. On a second hand, our preclinical stem cell-based technology allows assessing drug candidate efficiency on patient-derived models. We are building a fully integrated workflow to conduct clinical trials in a dish to leverage the most of preclinical data and ensure the highest success rate during large scale clinical trials.